PTPN11 and myeloproliferative disorder: Using specifically expressed cre, such as Prx1-cre (Greenbaum et al., 2013), nestin-cre (Méndez-Ferrer et al., 2010), Lepr-cre (Ding et al., 2012), and Osterix-cre (Tang et al., 2016), to induce PTPN11 mutations in bone marrow mesenchymal cells leads to MPN, but SHP2 mutations in endothelial cells (VE-Cadherin-cre) and osteoblasts (Oc-cre) will not lead to MPN formation (Dong et al., 2016), which indicates that SHP2 mutations in the specific components of bone marrow microenvironment show leukemogenic effects (Figure 3).